Literature DB >> 12562589

Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression.

Julia Davies1, Keith R Lloyd, Ivor K Jones, Anna Barnes, Lyn S Pilowsky.   

Abstract

OBJECTIVE: Neuroimaging studies reveal abnormalities of regional cerebral blood flow (rCBF) in major depression. In this study the authors prospectively investigated rCBF and clinical response to venlafaxine, a novel antidepressant.
METHOD: A trial of venlafaxine was performed with seven patients referred with ICD-10 major depression. At entry and 6-week follow-up, the Beck Depression Inventory and Hamilton Depression Rating Scale were administered and rCBF was measured by means of single photon emission computed tomography with [(99m)Tc]hexamethylpropyleneamine oxime. Blood flow changes were explored with statistical parametric mapping.
RESULTS: The subjects showed significant improvement after treatment. Statistical parametric mapping analysis revealed increased rCBF bilaterally in the thalamus and decreased rCBF in the left occipital lobe, right cerebellum, and temporal cortex bilaterally.
CONCLUSIONS: These data confirm limbic cortical rCBF changes associated with effective antidepressant treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562589     DOI: 10.1176/appi.ajp.160.2.374

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  19 in total

1.  Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging.

Authors:  Sakthivel Sekar; M Verhoye; J Van Audekerke; G Vanhoutte; Andrew S Lowe; Andrew M Blamire; Thomas Steckler; A Van der Linden; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2010-11-20       Impact factor: 4.530

Review 2.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

3.  A pattern of cerebral perfusion anomalies between major depressive disorder and Hashimoto thyroiditis.

Authors:  Maria Carolina Hardoy; Mariangela Cadeddu; Alessandra Serra; Maria Francesca Moro; Gioia Mura; Gisa Mellino; Krishna M Bhat; Gianmarco Altoé; Paolo Usai; Mario Piga; Mauro G Carta
Journal:  BMC Psychiatry       Date:  2011-09-13       Impact factor: 3.630

4.  Assessing regional cerebral blood flow in depression using 320-slice computed tomography.

Authors:  Yiming Wang; Hongming Zhang; Songlin Tang; Xingde Liu; Adrienne O'Neil; Alyna Turner; Fangxian Chai; Fanying Chen; Michael Berk
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

Review 5.  Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2013-07-03       Impact factor: 3.911

6.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

7.  A meta-analytic study of changes in brain activation in depression.

Authors:  Paul B Fitzgerald; Angela R Laird; Jerome Maller; Zafiris J Daskalakis
Journal:  Hum Brain Mapp       Date:  2008-06       Impact factor: 5.038

Review 8.  Steroids, sex and the cerebellar cortex: implications for human disease.

Authors:  Shannon L Dean; Margaret M McCarthy
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

9.  Longitudinal study of chronic depressive symptoms and regional cerebral blood flow in older men and women.

Authors:  Vonetta M Dotson; Lori Beason-Held; Michael A Kraut; Susan M Resnick
Journal:  Int J Geriatr Psychiatry       Date:  2009-08       Impact factor: 3.485

10.  The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task.

Authors:  Emma J Rose; Enrico Simonotto; Edgar P Spencer; Klaus P Ebmeier
Journal:  Psychopharmacology (Berl)       Date:  2006-03-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.